Pegavision Corporation (6491.TW)
TWD 330.5
(1.85%)
TWD 330.5
(1.85%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.91 Billion TWD | 5.51% |
| 2022 | 2.76 Billion TWD | 30.82% |
| 2021 | 2.11 Billion TWD | 44.66% |
| 2020 | 1.46 Billion TWD | 15.22% |
| 2019 | 1.26 Billion TWD | -1.51% |
| 2018 | 1.28 Billion TWD | 102.08% |
| 2017 | 637.27 Million TWD | 32.08% |
| 2016 | 482.48 Million TWD | 31.99% |
| 2015 | 365.55 Million TWD | 80.43% |
| 2014 | 202.6 Million TWD | 55.79% |
| 2013 | 130.04 Million TWD | 1075.2% |
| 2012 | -13.33 Million TWD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 794.82 Million TWD | -13.68% |
| 2024 Q2 | 720.14 Million TWD | -9.4% |
| 2024 Q3 | 705.84 Million TWD | -1.99% |
| 2023 Q1 | 655.26 Million TWD | -12.08% |
| 2023 Q3 | 723.59 Million TWD | 3.86% |
| 2023 Q2 | 696.69 Million TWD | 6.32% |
| 2023 Q4 | 920.77 Million TWD | 27.25% |
| 2023 FY | - TWD | 5.51% |
| 2022 Q4 | 745.31 Million TWD | 1.58% |
| 2022 Q2 | 644.92 Million TWD | 0.5% |
| 2022 FY | - TWD | 30.82% |
| 2022 Q1 | 641.72 Million TWD | -1.0% |
| 2022 Q3 | 733.7 Million TWD | 13.77% |
| 2021 Q1 | 394.17 Million TWD | -16.71% |
| 2021 FY | - TWD | 44.66% |
| 2021 Q4 | 648.19 Million TWD | 8.55% |
| 2021 Q3 | 597.16 Million TWD | 25.86% |
| 2021 Q2 | 474.47 Million TWD | 20.37% |
| 2020 Q2 | 325.56 Million TWD | 19.26% |
| 2020 FY | - TWD | 15.22% |
| 2020 Q3 | 389.58 Million TWD | 19.66% |
| 2020 Q1 | 272.99 Million TWD | -24.89% |
| 2020 Q4 | 473.24 Million TWD | 21.47% |
| 2019 Q3 | 313.17 Million TWD | 12.09% |
| 2019 Q2 | 279.38 Million TWD | -10.56% |
| 2019 Q1 | 312.38 Million TWD | -13.18% |
| 2019 FY | - TWD | -1.51% |
| 2019 Q4 | 363.44 Million TWD | 16.05% |
| 2018 Q4 | 359.81 Million TWD | -6.59% |
| 2018 FY | - TWD | 102.08% |
| 2018 Q3 | 385.19 Million TWD | 108.66% |
| 2018 Q2 | 184.6 Million TWD | -31.07% |
| 2018 Q1 | 267.82 Million TWD | 59.55% |
| 2017 Q3 | 167.86 Million TWD | 17.22% |
| 2017 Q1 | 143.2 Million TWD | 10.24% |
| 2017 FY | - TWD | 32.08% |
| 2017 Q4 | 167.86 Million TWD | 0.0% |
| 2017 Q2 | 143.2 Million TWD | 0.0% |
| 2016 Q1 | 108.99 Million TWD | 16.16% |
| 2016 Q2 | 108.99 Million TWD | 0.0% |
| 2016 Q3 | 129.9 Million TWD | 19.18% |
| 2016 FY | - TWD | 31.99% |
| 2016 Q4 | 129.9 Million TWD | 0.0% |
| 2015 Q4 | 93.83 Million TWD | 0.0% |
| 2015 Q2 | 76.99 Million TWD | 0.0% |
| 2015 Q3 | 93.83 Million TWD | 21.86% |
| 2015 Q1 | 76.99 Million TWD | 37.46% |
| 2015 FY | - TWD | 80.43% |
| 2014 Q2 | 37.63 Million TWD | 0.0% |
| 2014 Q3 | 56.01 Million TWD | 48.84% |
| 2014 FY | - TWD | 55.79% |
| 2014 Q4 | 56.01 Million TWD | 0.0% |
| 2014 Q1 | 37.63 Million TWD | 38.0% |
| 2013 Q2 | 28.46 Million TWD | 0.0% |
| 2013 Q4 | 27.27 Million TWD | 0.0% |
| 2013 Q1 | 28.46 Million TWD | 0.0% |
| 2013 FY | - TWD | 1075.2% |
| 2013 Q3 | 27.27 Million TWD | -4.18% |
| 2012 FY | - TWD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd. | 402.69 Million TWD | -624.626% |
| Maxigen Biotech Inc. | 177.09 Million TWD | -1547.752% |
| SciVision Biotech Inc. | 281.34 Million TWD | -937.169% |
| Bionime Corporation | 179.78 Million TWD | -1523.115% |
| Visco Vision Inc. | 733.58 Million TWD | -297.779% |